Literature DB >> 1335707

Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs.

R D Walker1, G E Stein, J G Hauptman, K H MacDonald.   

Abstract

Enrofloxacin was administered orally to 6 healthy dogs at dosages of approximately 2.75, 5.5, and 11 mg/kg of body weight, every 12 hours for 4 days, with a 4-week interval between dosage regimens. Serum and tissue cage fluid (TCF) concentrations of enrofloxacin were measured after the first and seventh treatments. The mean peak serum concentration occurred between 1 and 2.5 hours after dosing. Peak serum concentrations increased with increases in dosage. For each dosage regimen, there was an accumulation of enrofloxacin between the first and seventh treatment, as demonstrated by a significant (P = 0.001) increase in peak serum concentrations. The serum elimination half-life increased from 3.39 hours for the 2.75 mg/kg dosage to 4.94 hours for the 11 mg/kg dosage. Enrofloxacin accumulated slowly into TCF, with peak concentrations being approximately 58% of those of serum. The time of peak TCF concentrations occurred between 3.8 hours and 5.9 hours after drug administration, depending on the dosage and whether it was after single or multiple administrations. Compared with serum concentrations (area under the curve TCF/area under the curve serum), the percentage of enrofloxacin penetration into TCF was 85% at a dosage of 2.75 mg/kg, 83% at a dosage of 5.5 mg/kg, and 88% at a dosage of 11 mg/kg. All 3 dosage regimens of enrofloxacin induced continuous serum and TCF concentrations greater than the minimal concentration required to inhibit 90% (MIC90) of the aerobic and facultative anaerobic clinical isolates tested, except Pseudomonas aeruginosa.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335707

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  8 in total

1.  Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves.

Authors:  A K Srivastava; V K Dumka; S S Deol
Journal:  Vet Res Commun       Date:  2000-04       Impact factor: 2.459

2.  Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in male and female turkeys following intravenous and oral administration.

Authors:  D J Dimitrova; L D Lashev; St G Yanev; V T Pandova
Journal:  Vet Res Commun       Date:  2006-05       Impact factor: 2.459

3.  Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration.

Authors:  Q McKellar; I Gibson; A Monteiro; M Bregante
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Pharmacokinetics of enrofloxacin after intravenous and intramuscular administration in Angora goats.

Authors:  M Elmas; B Tras; S Kaya; A L Bas; E Yazar; E Yarsan
Journal:  Can J Vet Res       Date:  2001-01       Impact factor: 1.310

5.  Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats.

Authors:  G S Rao; S Ramesh; A H Ahmad; H C Tripathi; L D Sharma; J K Malik
Journal:  Vet Res Commun       Date:  2001-04       Impact factor: 2.459

6.  Eco-toxic effects of sulfadiazine sodium, sulfamonomethoxine sodium and enrofloxacin on wheat, Chinese cabbage and tomato.

Authors:  Caixia Jin; Qiuying Chen; Ruilian Sun; Qingxiang Zhou; Junjun Liu
Journal:  Ecotoxicology       Date:  2009-06-25       Impact factor: 2.823

7.  Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines.

Authors:  Kyoung won Seo; Roseline Holt; Yong-Sam Jung; Carlos O Rodriguez; Xinbin Chen; Robert B Rebhun
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

8.  Induction of a chronic myocardial infarction in the laboratory animal - experimental model.

Authors:  Ionel Ciprian Pop; Nicolae-Ovidiu Grad; Cosmin Pestean; Marian Taulescu; Mircea Mircean; Ion-Aurel Mironiuc
Journal:  Clujul Med       Date:  2013-11-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.